cannabis indica

Hidrolase de Amidas de Ácidos Graxos (FAAH)

termo de indexação original: Fatty Acid Amide Hydrolase (FAAH)

O que é Hidrolase de Amidas de Ácidos Graxos (FAAH)

A hidrolase de amidas de ácidos graxos, conhecida pela sigla inglesa FAAH, é a enzima que quebra a anandamida e outras amidas de ácidos graxos, encerrando sua ação. É ela que faz o sinal endocanabinoide ser breve.

Por isso a FAAH virou alvo farmacológico: inibir a enzima eleva os níveis de anandamida no próprio tecido onde ela foi produzida, sem introduzir um canabinoide externo. A ideia é modular o sistema onde ele já está ativo, em vez de ativá-lo por inteiro — o que, em tese, evitaria os efeitos psicoativos generalizados.

Boa parte dos estudos que citam a FAAH neste acervo testa inibidores dessa enzima em modelos de dor, ansiedade e inflamação. Vale registrar que essa linha também produziu um episódio conhecido de segurança: um ensaio clínico de fase 1 com um inibidor de FAAH na França, em 2016, resultou em dano neurológico grave e uma morte — um lembrete de que modular o sistema endocanabinoide não é trivial.

No acervo

O acervo do Cannabis Indica reúne 358 estudos científicos que tocam o composto Hidrolase de Amidas de Ácidos Graxos (FAAH), publicados entre 1997 e 2024. Pela leitura automatizada, 288 (80%) foram classificados como favoráveis, 57 (16%) como inconclusivos e 13 (4%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (173 estudos), seguido de estudo em animais (102). As condições mais associadas são Inflamação, Ansiedade e Dor.

Estudos indexados
358
Período coberto
1997–2024
Favoráveis
288 · 80%
Inconclusivos
57 · 16%
Desfavoráveis
13 · 4%
Termo original
Fatty Acid Amide Hydrolase (FAAH)

O acervo em números

Tipo de estudo

Metanálise173
Estudo em Animais102
Ensaio Clínico31
Estudo Laboratorial28
Ensaio Clínico Duplo-Cego20
Metanálise Clínica4

Direção do resultado

Favorável288
Inconclusivo57
Desfavorável13

Por década

1990s1
2000s37
2010s172
2020s148

358 estudos

Filtrar e buscar no acervo →

Esta página mostra 303 dos 358 estudos indexados sobre o tema, dos mais recentes aos mais antigos. Abra o acervo com este filtro para percorrer todos, ou baixe a lista completa em JSON e CSV.

  1. 2024

    A systematic review of novel cannabinoids and their targets: Insights into the significance of structure in activity

    InconclusivoMetanáliseAnandamida (AEA)Endocanabinoide (não especificado)+3
  2. 2024

    Bovine Colostrum Increases Intestinal Permeability in Healthy Athletes and Patients: A Meta-Analysis of Randomized Clinical Trials

    DesfavorávelMetanáliseInflamaçãoDII — Doença Inflamatória Intestinal
  3. 2024

    Cannabinoid Analgesia in Postoperative Pain Management: From Molecular Mechanisms to Clinical Reality

    InconclusivoMetanáliseDorDor — AgudaAnandamida (AEA)Tetraidrocanabinol (THC)+7
  4. 2024

    Dietary linoleic acid lowering alone does not lower arachidonic acid or endocannabinoids among women with overweight and obesity: A randomized, controlled trial

  5. 2024

    Editorial: Insights on cannabinoid translational science and medicine: the endocannabinoidome as a target for clinical practice

    FavorávelMetanáliseAnandamida (AEA)Tetraidrocanabinol (THC)+9
  6. 2024

    Endocannabinoid Hydrolase Inhibitors: Potential Novel Anxiolytic Drugs

    FavorávelMetanáliseAnsiedadeAnandamida (AEA)Endocanabinoide (não especificado)+4
  7. 2024

    Neurolipidomic insights into anxiety disorders: Uncovering lipid dynamics for potential therapeutic advances

  8. 2024

    Nutrient composition of different energy-restricted diets determines plasma endocannabinoid profiles and adipose tissue DAGL-α expression; a 12-week randomized controlled trial in subjects with abdominal obesity

  9. 2023

    A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis

    FavorávelEnsaio Clínico Duplo-CegoDiabetesGastroparesiaCBD Farmacêutico
  10. 2023

    A systematic review of cannabidiol trials in neurodevelopmental disorders

    FavorávelMetanálise ClínicaDorInflamaçãoAnsiedadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+10
  11. 2023

    Almond Consumption for 8 Weeks Altered Host and Microbial Metabolism in Comparison to a Control Snack in Young Adults

  12. 2023

    Anandamide reduces the migration of lymphocytes to the intestine by CB2 activation and reduces TNF-α in the target organs, protecting mice from graft-versus-host disease

  13. 2023

    Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance

  14. 2023

    Cannabinoid Receptor 2 Blockade Prevents Anti-Depressive-like Effect of Cannabidiol Acid Methyl Ester in Female WKY Rats

    FavorávelEstudo em AnimaisDepressãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+4
  15. 2023

    Cannabinoid receptor type 1 (CB1R) inhibits hypothalamic leptin signaling via β-arrestin1 in complex with TC-PTP and STAT3

  16. 2023

    CB1 receptor expression and signaling are required for dexamethasone-induced aversive memory consolidation

  17. 2023

    Could cannabinoids provide a new hope for ovarian cancer patients?

  18. 2023

    Endocannabinoid 2-Arachidonoylglycerol Synthesis and Metabolism at Neuronal Nuclear Matrix Fractions Derived from Adult Rat Brain Cortex

    FavorávelEstudo LaboratorialEstresse OxidativoAnandamida (AEA)Endocanabinoide (não especificado)+2
  19. 2023

    Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review

  20. 2023

    N-oleoyl glycine and N-oleoyl alanine attenuate alcohol self-administration and preference in mice

  21. 2023

    Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer's disease: A systematic review and meta-analysis of animal studies

  22. 2023

    The Effects of Peripubertal THC Exposure in Neurodevelopmental Rat Models of Psychopathology

  23. 2022

    (Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders

  24. 2022

    A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ

  25. 2022

    Activation of the endocannabinoid system mediates cardiac hypertrophy induced by rosiglitazone

  26. 2022

    Acute and long-term exercise differently modulate plasma levels of oxylipins, endocannabinoids, and their analogues in young sedentary adults: A sub-study and secondary analyses from the ACTIBATE randomized controlled-trial

  27. 2022

    Amygdalar CB2 cannabinoid receptor mediates fear extinction deficits promoted by orexin-A/hypocretin-1

  28. 2022

    Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico

  29. 2022

    Cannabidiol for Functional Dyspepsia With Normal Gastric Emptying: A Randomized Controlled Trial

    InconclusivoEnsaio Clínico Duplo-CegoNáusea e VômitoRefluxo GastroesofágicoÚlcera Gástrica+1
  30. 2022

    Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study

  31. 2022

    Cannabinoids as anticancer drugs: current status of preclinical research

  32. 2022

    Cannabinoids as Glial Cell Modulators in Ischemic Stroke: Implications for Neuroprotection

  33. 2022

    Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth?

  34. 2022

    Cannabinoids in rheumatology: Friend, foe or a bystander?

  35. 2022

    Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials

  36. 2022

    Cannabinoids: Therapeutic Use in Clinical Practice

  37. 2022

    Cannabis Use and the Endocannabinoid System: A Clinical Perspective

  38. 2022

    Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review

    FavorávelMetanáliseDorCâncerInflamaçãoAnandamida (AEA)Tetraidrocanabinol (THC)+28
  39. 2022

    Changes in the expression of endocannabinoid system components in an experimental model of chemotherapy-induced peripheral neuropathic pain: Evaluation of sex-related differences

  40. 2022

    Circulating endocannabinoids and genetic polymorphisms as predictors of posttraumatic stress disorder symptom severity: heterogeneity in a community-based cohort

    InconclusivoEnsaio ClínicoTEPTAnandamida (AEA)Endocanabinoide (não especificado)+1
  41. 2022

    Curcumin induces peripheral antinociception by opioidergic and cannabinoidergic mechanism: Pharmacological evidence

  42. 2022

    Differential expression of the neuronal CB1 cannabinoid receptor in the hippocampus of male Ts65Dn Down syndrome mouse model

    FavorávelEstudo em AnimaisSíndrome de DownAnandamida (AEA)Endocanabinoide (não especificado)+3
  43. 2022

    Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia

  44. 2022

    Effect of the MAGL/FAAH Dual Inhibitor JZL-195 on Streptozotocin-Induced Alzheimer's Disease-like Sporadic Dementia in Mice with an Emphasis on Aβ, HSP-70, Neuroinflammation, and Oxidative Stress

  45. 2022

    Effects of endocannabinoid system modulation on social behaviour: A systematic review of animal studies

  46. 2022

    Effects of non‐steroidal anti‐inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID‐19

  47. 2022

    Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes

    FavorávelEstudo LaboratorialDoenças de PeleAnandamida (AEA)Endocanabinoide (não especificado)+7
  48. 2022

    Endocannabinoid metabolism inhibition ameliorates ovalbumin-induced allergic airway inflammation and hyperreactivity in Guinea pigs

    FavorávelEstudo em AnimaisInflamaçãoAsmaMonoacilglicerol Lipase (MAGL)
  49. 2022

    Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty

  50. 2022

    Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells

  51. 2022

    Endocannabinoid signaling in glioma

  52. 2022

    Enhancing exposure therapy for posttraumatic stress disorder (PTSD): a randomized clinical trial of virtual reality and imaginal exposure with a cognitive enhancer

    FavorávelEnsaio Clínico Duplo-CegoDepressãoTEPT
  53. 2022

    Exploring the endocannabinoidome in genetically obese (ob/ob) and diabetic (db/db) mice: Links with inflammation and gut microbiota

  54. 2022

    FABP5 deletion in nociceptors augments endocannabinoid signaling and suppresses TRPV1 sensitization and inflammatory pain

    FavorávelEstudo em AnimaisDorAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+4
  55. 2022

    Fatty Acid Amide Hydrolase (FAAH) Inhibition Plays a Key Role in Counteracting Acute Lung Injury

    FavorávelEstudo em AnimaisInflamaçãoEstresse OxidativoFibroseAnandamida (AEA)+1
  56. 2022

    Fatty Acid Amide Hydrolase Deficiency Is Associated with Deleterious Cardiac Effects after Myocardial Ischemia and Reperfusion in Mice

  57. 2022

    Footshock-Induced Abstinence from Compulsive Methamphetamine Self-administration in Rat Model Is Accompanied by Increased Hippocampal Expression of Cannabinoid Receptors (CB1 and CB2)

  58. 2022

    G Protein-Coupled Receptors in Osteoarthritis

  59. 2022

    Gene Expression Analysis of the Endocannabinoid System in Presymptomatic APP/PS1 Mice

  60. 2022

    Higher trait neuroticism is associated with greater fatty acid amide hydrolase binding in borderline and antisocial personality disorders

    FavorávelEnsaio ClínicoTranstornos de ComportamentoTranstorno BipolarLutoAnandamida (AEA)+2
  61. 2022

    Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders

  62. 2022

    Impact of cyclooxygenase-2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers

  63. 2022

    In it together? The case for endocannabinoid–noradrenergic interactions in fear extinction

  64. 2022

    Influence of diet on acute endocannabinoidome mediator levels post exercise in active women, a crossover randomized study

  65. 2022

    Inhibiting Endocannabinoid Hydrolysis as Emerging Analgesic Strategy Targeting a Spectrum of Ion Channels Implicated in Migraine Pain

    FavorávelMetanáliseEnxaquecaAnandamida (AEA)Endocanabinoide (não especificado)+4
  66. 2022

    Inhibiting the endocannabinoid degrading enzymes FAAH and MAGL during zebrafish embryogenesis alters sensorimotor function

    FavorávelEstudo LaboratorialEndocanabinoide (não especificado)Monoacilglicerol Lipase (MAGL)
  67. 2022

    Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies

  68. 2022

    Long-term observational studies with cannabis-based medicines for chronic non-cancer pain: A systematic review and meta-analysis of effectiveness and safety

  69. 2022

    Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence

  70. 2022

    Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice

  71. 2022

    Practical Considerations for the Use of Cannabis in Cancer Pain Management—What a Medical Oncologist Should Know

  72. 2022

    Processing cardiovascular information in the vlPAG during electroacupuncture in rats: roles of endocannabinoids and GABA

    FavorávelEstudo em AnimaisDoenças Cardiovasculares (DCV)Acupuntura (MTC)
  73. 2022

    Role of cannabis in inflammatory bowel diseases

  74. 2022

    Role of the endocannabinoid system in the pathophysiology of endometriosis and therapeutic implications

  75. 2022

    Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations

  76. 2022

    Synaptic changes induced by cannabinoid drugs and cannabis use disorder

  77. 2022

    Targeting the Endocannabinoidome in Pancreatic Cancer

  78. 2022

    Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report

    FavorávelMetanáliseInflamaçãoAnsiedadeDepressãoAnandamida (AEA)+6
  79. 2022

    The Autism–Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System

  80. 2022

    The Effect of Oleoylethanolamide (OEA) Add-On Treatment on Inflammatory, Oxidative Stress, Lipid, and Biochemical Parameters in the Acute Ischemic Stroke Patients: Randomized Double-Blind Placebo-Controlled Study

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoAnsiedadeAnandamida (AEA)Oleoiletanolamida (OEA)+7
  81. 2022

    The Endocannabinoid System and Physical Activity—A Robust Duo in the Novel Therapeutic Approach against Metabolic Disorders

  82. 2022

    The Endocannabinoid System as a Biomarker for Diagnostic and Therapeutic Applications in Depression and Anxiety

  83. 2022

    The Role of Nutritional Status, Gastrointestinal Peptides, and Endocannabinoids in the Prognosis and Treatment of Children with Cancer

    InconclusivoMetanáliseDorCâncerObesidadeAnandamida (AEA)Tetraidrocanabinol (THC)+17
  84. 2022

    The role of the cannabinoid system in fear memory and extinction in male and female mice

    InconclusivoEstudo em AnimaisTEPTAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+4
  85. 2022

    Translation of animal endocannabinoid models of PTSD mechanisms to humans: Where to next?

    FavorávelMetanáliseTEPTAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  86. 2022

    Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?

  87. 2021

    A systematic, integrative review of the effects of the endocannabinoid system on inflammation and neurogenesis in animal models of affective disorders

  88. 2021

    An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner's lesions

    InconclusivoEnsaio ClínicoCanabinoide Sintético (não especificado)
  89. 2021

    Anti-Inflammatory Effects of Fatty Acid Amide Hydrolase Inhibition in Monocytes/Macrophages from Alzheimer's Disease Patients

    FavorávelEstudo LaboratorialDoença de Alzheimer
  90. 2021

    Anticancer Potential of Small-Molecule Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase

  91. 2021

    Cannabidiol and Neurodevelopmental Disorders in Children

  92. 2021

    Cannabinoid receptor type 2 gene is associated with comorbidity of schizophrenia and cannabis dependence and fatty acid amide hydrolase gene is associated with cannabis dependence in the Spanish population

  93. 2021

    Cannabis and Autoimmunity: Possible Mechanisms of Action

  94. 2021

    Cannabis and Inflammation in HIV: A Review of Human and Animal Studies

  95. 2021

    Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC

    FavorávelMetanáliseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+17
  96. 2021

    Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine

    FavorávelEstudo em AnimaisEnxaquecaAnandamida (AEA)
  97. 2021

    Circulating endocannabinoids and prospective risk for depression in trauma-injury survivors

    InconclusivoMetanáliseDepressãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  98. 2021

    Comorbid anxiety-like behavior in a rat model of colitis is mediated by an upregulation of corticolimbic fatty acid amide hydrolase

  99. 2021

    Computational Approach Reveals Pronociceptive Potential of Cannabidiol in Osteoarthritis: Role of Transient Receptor Potential Channels

  100. 2021

    Contribution of Fatty Acid Amide Hydrolase to Alcohol Use Disorder: A Systematic Review

    InconclusivoMetanáliseDependência QuímicaDependência — ÁlcoolAnandamida (AEA)
  101. 2021

    Endocannabinoid Anandamide Attenuates Acute Respiratory Distress Syndrome through Modulation of Microbiome in the Gut-Lung Axis

    FavorávelEstudo em AnimaisCOVID-19Desequilíbrio do MicrobiomaEstresseAnandamida (AEA)Microbioma+1
  102. 2021

    Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review

  103. 2021

    Endocannabinoid System as Therapeutic Target of PTSD: A Systematic Review

    FavorávelMetanáliseTEPTEndocanabinoide (não especificado)THC Farmacêutico
  104. 2021

    Genetic Variants of Fatty Acid Amide Hydrolase Modulate Acute Inflammatory Responses to Colitis in Adult Male Mice

  105. 2021

    Genetics of methamphetamine use disorder: A systematic review and meta-analyses of gene association studies

    FavorávelMetanáliseDependência QuímicaDependência — Estimulantes
  106. 2021

    High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients

  107. 2021

    Impact of saffron (Crocus Sativus Linn) supplementation and resistance training on markers implicated in depression and happiness levels in untrained young males

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeDepressãoAnandamida (AEA)
  108. 2021

    Inhibition of Fatty Acid Amide Hydrolase (FAAH) During Adolescence and Exposure to Early Life Stress may Exacerbate Depression-like Behaviors in Male and Female Rats

    FavorávelEstudo em AnimaisDepressão
  109. 2021

    Lifestyle Interventions Improving Cannabinoid Tone During COVID-19 Lockdowns May Enhance Compliance With Preventive Regulations and Decrease Psychophysical Health Complications

  110. 2021

    Linking the Endocannabinoidome with Specific Metabolic Parameters in an Overweight and Insulin-Resistant Population: From Multivariate Exploratory Analysis to Univariate Analysis and Construction of Predictive Models

  111. 2021

    Metabolic Consequences of Gestational Cannabinoid Exposure

  112. 2021

    Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions

  113. 2021

    New Insights in the Involvement of the Endocannabinoid System and Natural Cannabinoids in Nicotine Dependence

  114. 2021

    Pharmacology, Clinical Effects, and Therapeutic Potential of Cannabinoids for Gastrointestinal and Liver Diseases

  115. 2021

    Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis

  116. 2021

    Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition

  117. 2021

    Protective role of endocannabinoid signaling in an animal model of haloperidol-induced tardive dyskinesia

    FavorávelEstudo em AnimaisDistoniaCoreiaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  118. 2021

    Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders

  119. 2021

    Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers

    DesfavorávelEnsaio Clínico Duplo-CegoAnandamida (AEA)
  120. 2021

    The effects of FAAH inhibition on the neural basis of anxiety-related processing in healthy male subjects: a randomized clinical trial

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeTEPTAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  121. 2021

    The Effects of Intermittent Hypoxic-Hyperoxic Exposures on Lipid Profile and Inflammation in Patients With Metabolic Syndrome

    FavorávelEnsaio ClínicoInflamaçãoDoenças Cardiovasculares (DCV)Obesidade+3
  122. 2021

    The effects of systemic and local fatty acid amide hydrolase and monoacylglycerol lipase inhibitor treatments on the metabolomic profile of lungs

    FavorávelEstudo em AnimaisInflamaçãoFibroseAsmaMonoacilglicerol Lipase (MAGL)+1
  123. 2021

    The Endocannabinoid System as Modulator of Exercise Benefits in Mental Health

    FavorávelMetanáliseDepressãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
  124. 2021

    The influence of FAAH genetic variation on physiological, cognitive, and neural signatures of fear acquisition and extinction learning in women with PTSD

    FavorávelEnsaio ClínicoTEPTAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  125. 2021

    The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?

  126. 2021

    The role of fatty acid amide hydrolase enzyme inhibitors in Alzheimer's disease

    FavorávelMetanáliseDoença de AlzheimerAnandamida (AEA)
  127. 2021

    Understanding the complex pharmacology of cannabidiol: Mounting evidence suggests a common binding site with cholesterol

    InconclusivoMetanáliseDoenças Cardiovasculares (DCV)InfartoCBD Farmacêutico
  128. 2021

    URB597 Prevents the Short-Term Excitotoxic Cell Damage in Rat Cortical Slices: Role of Cannabinoid 1 Receptors

    FavorávelEstudo LaboratorialExcitotoxicidadeAnandamida (AEA)
  129. 2020

    Assessment of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial

  130. 2020

    Beyond THC and Endocannabinoids

  131. 2020

    Cannabinoids and Chronic Liver Diseases

  132. 2020

    Cannabinoids, Endocannabinoids and Sleep

  133. 2020

    Chronic Cannabidiol Administration Fails to Diminish Blood Pressure in Rats With Primary and Secondary Hypertension Despite Its Effects on Cardiac and Plasma Endocannabinoid System, Oxidative Stress and Lipid Metabolism

  134. 2020

    Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat

  135. 2020

    Effect of flaxseed oil supplementation on the erythrocyte membrane fatty acid composition and endocannabinoid system modulation in patients with coronary artery disease: a double-blind randomized controlled trial

  136. 2020

    Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder

    FavorávelMetanáliseDependência QuímicaDependência — Cannabis
  137. 2020

    GPR119 Is a Potent Regulator of Human Sebocyte Biology

    FavorávelEstudo LaboratorialCâncerInflamaçãoDiabetesAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+4
  138. 2020

    Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity

  139. 2020

    Mgll Knockout Mouse Resistance to Diet-Induced Dysmetabolism Is Associated with Altered Gut Microbiota

  140. 2020

    Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease

  141. 2020

    N-Acylphosphatidylethanolamines and N-acylethanolamines increase in saliva upon food mastication: the influence of the individual nutritional status and fat type in food

    FavorávelEnsaio ClínicoObesidadeAnandamida (AEA)Endocanabinoide (não especificado)+1
  142. 2020

    Neural Stem Cells and Cannabinoids in the Spotlight as Potential Therapy for Epilepsy

    FavorávelMetanáliseEpilepsiaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  143. 2020

    Oral Supplementation with Ultramicronized Palmitoylethanolamide for Joint Disease and Lameness Management in Four Jumping Horses: A Case Report

    FavorávelEstudo em Animais
  144. 2020

    Role of the endocannabinoid system in the regulation of the skeletal muscle response to exercise

  145. 2020

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study

    FavorávelEnsaio Clínico Duplo-Cego
  146. 2020

    The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeDepressãoDisfunção CognitivaAnandamida (AEA)Palmitoiletanolamida (PEA)+2
  147. 2020

    The Endocannabinoid System and Synthetic Cannabinoids in Preclinical Models of Seizure and Epilepsy

  148. 2020

    The Endocannabinoid System May Modulate Sleep Disorders in Aging

  149. 2019

    Acute naloxone-precipitated morphine withdrawal elicits nausea-like somatic behaviors in rats in a manner suppressed by N-oleoylglycine

  150. 2019

    Add-on administration of ultramicronized palmitoylethanolamide in the treatment of new-onset burning mouth syndrome

    FavorávelMetanáliseSíndrome da Boca Ardente
  151. 2019

    Cannabinoid Regulation of Fear and Anxiety: an Update

    FavorávelMetanáliseAnsiedadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  152. 2019

    Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System

  153. 2019

    Cannabinoids and Dementia: A Review of Clinical and Preclinical Data

  154. 2019

    Endocannabinoid System and the Kidneys: From Renal Physiology to Injury and Disease

  155. 2019

    Endocannabinoid System Components as Potential Biomarkers in Psychiatry

  156. 2019

    Fatty Acid Amide Hydrolase Inhibition Normalises Bladder Function and Reduces Pain Through Normalising the Anandamide/Palmitoylethanolamine Ratio in the Inflamed Bladder of Rats

    FavorávelEstudo em AnimaisCistiteAnandamida (AEA)Outros Compostos Relacionados
  157. 2019

    Future Aspects for Cannabinoids in Breast Cancer Therapy

  158. 2019

    Hypothalamic endocannabinoid signalling modulates aversive responses related to panic attacks.

    FavorávelEstudo em AnimaisAnsiedadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+5
  159. 2019

    Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain

    FavorávelEstudo em AnimaisDorDor — CrônicaDepressão
  160. 2019

    Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome

  161. 2019

    Lower circulating endocannabinoid levels in children with autism spectrum disorder

    InconclusivoMetanáliseAutismoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
  162. 2019

    Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer

  163. 2019

    Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity

    FavorávelMetanáliseDorAnsiedadeDor — CrônicaAnandamida (AEA)+2
  164. 2019

    Opposite roles of cannabinoid receptor 1 and 2 in hepatocarcinogenesis

  165. 2019

    Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity

  166. 2019

    Peripheral changes of endocannabinoid system components in episodic and chronic migraine patients: A pilot study

    FavorávelMetanáliseEnxaquecaAnandamida (AEA)
  167. 2019

    Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents

    InconclusivoMetanálise
  168. 2019

    Plants come to mind: phytocannabinoids, endocannabinoids and the control of seizures

  169. 2019

    Potential Use of Cannabinoids for the Treatment of Pancreatic Cancer

  170. 2019

    Repetitive high-frequency transcranial magnetic stimulation reverses depressive-like behaviors and protein expression at hippocampal synapses in chronic unpredictable stress-treated rats by enhancing endocannabinoid signaling

    FavorávelEstudo em AnimaisDepressãoAnandamida (AEA)Endocanabinoide (não especificado)+3
  171. 2019

    Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome

  172. 2019

    The Endocannabinoid System as a Window Into Microglial Biology and Its Relationship to Autism

  173. 2019

    The Endocannabinoid System of Animals

  174. 2019

    The influence of the fatty acid amide hydrolase 385C>A single nucleotide polymorphisms on obesity susceptibility

    InconclusivoMetanáliseObesidadeEndocanabinoide (não especificado)
  175. 2019

    Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy with Different Antioxidant Molecules Present in Diets

  176. 2019

    Translating Endocannabinoid Biology into Clinical Practice: Cannabidiol for Stroke Prevention

  177. 2019

    Upregulation of Anandamide Hydrolysis in the Basolateral Complex of Amygdala Reduces Fear Memory Expression and Indices of Stress and Anxiety.

    FavorávelEstudo em AnimaisAnsiedadeAnandamida (AEA)Outros Compostos Relacionados
  178. 2018

    Anandamide and endocannabinoid system: an attractive therapeutic approach for cardiovascular disease

    FavorávelMetanáliseAnandamida (AEA)Canabinoides Sintéticos AM-x+4
  179. 2018

    Antitumorigenic Properties of Omega-3 Endocannabinoid Epoxides

  180. 2018

    Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials.

    FavorávelMetanáliseAnsiedadeTEPTAnandamida (AEA)
  181. 2018

    Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal.

    FavorávelEnsaio Clínico Duplo-CegoDependência QuímicaDependência — NicotinaAnandamida (AEA)
  182. 2018

    Cannabinoids and Gastrointestinal Motility: Pharmacology, Clinical Effects, and Potential Therapeutics in Humans

  183. 2018

    Cannabinoids, the Heart of the Matter.

  184. 2018

    Cannabis and pediatric inflammatory bowel disease: change blossoms a mile high.

  185. 2018

    Effects of Fatty Acid Amide Hydroxylase Inhibitor URB597 on the Catecholaminergic Activity of the Adrenal Medulla in Stressed Male and Female Rats

    FavorávelEstudo em AnimaisInflamaçãoEstresse Oxidativo
  186. 2018

    Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.

    FavorávelEnsaio Clínico Duplo-CegoEfeitos Adversos da CannabisDependência — CannabisAnandamida (AEA)
  187. 2018

    Emerging Role of (Endo)Cannabinoids in Migraine

    FavorávelMetanáliseEnxaquecaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  188. 2018

    Endocannabinoid system acts as a regulator of immune homeostasis in the gut.

    FavorávelEstudo em AnimaisDiabetesDesequilíbrio do MicrobiomaAnandamida (AEA)
  189. 2018

    Endocannabinoids in Body Weight Control

    FavorávelMetanáliseObesidadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+6
  190. 2018

    Fatty acid amide hydrolase (FAAH) blockade ameliorates experimental colitis by altering microRNA expression and suppressing inflammation.

  191. 2018

    Impaired anandamide/palmitoylethanolamide signaling in hippocampal glutamatergic neurons alters synaptic plasticity, learning, and emotional responses

  192. 2018

    Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's disease and Less Well-Known Diseases.

  193. 2018

    N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice

  194. 2018

    Neuroprotection by (Endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases

  195. 2018

    Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort

  196. 2018

    Potential of Endocannabinoids to Control Bladder Pain.

    FavorávelMetanáliseCistiteAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  197. 2018

    Protective effects of elevated anandamide on stress and fear-related behaviors: translational evidence from humans and mice.

    FavorávelEstudo em AnimaisAnsiedadeTEPTAnandamida (AEA)
  198. 2018

    Role of Endocannabinoids on Sweet Taste Perception, Food Preference, and Obesity-related Disorders

  199. 2018

    Role of the endocannabinoid system in neurological disorders.

    FavorávelMetanáliseAutismoAnandamida (AEA)Endocanabinoide (não especificado)+3
  200. 2018

    The Endocannabinoid System Affects Myocardial Glucose Metabolism in the DOCA-Salt Model of Hypertension.

    FavorávelEstudo em AnimaisDoenças Cardiovasculares (DCV)Hipertensão Arterial
  201. 2018

    The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain

  202. 2018

    Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis.

    FavorávelMetanáliseEsclerose MúltiplaAnandamida (AEA)Tetraidrocanabinol (THC)+9
  203. 2017

    A Pulsed Electromagnetic Field Protects against Glutamate-Induced Excitotoxicity by Modulating the Endocannabinoid System in HT22 Cells

  204. 2017

    Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn’s Disease

  205. 2017

    Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

  206. 2017

    Changes in the Brain Endocannabinoid System in Rat Models of Depression

    InconclusivoEstudo em AnimaisDepressãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  207. 2017

    Endocannabinoid system in sexual motivational processes: Is it a novel therapeutic horizon?

  208. 2017

    Endocannabinoids: A Promising Impact for Traumatic Brain Injury

  209. 2017

    Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial

    InconclusivoEnsaio Clínico Duplo-CegoInfecção Urinária
  210. 2017

    Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon.

  211. 2017

    Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine

    FavorávelMetanáliseEnxaquecaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  212. 2017

    Manipulation of the Endocannabinoid System in Colitis: A Comprehensive Review.

  213. 2017

    Recent advances in the endocrinology of the sebaceous gland

  214. 2017

    Restored Plasma Anandamide and Endometrial Expression of Fatty Acid Amide Hydrolase in Women With Polycystic Ovary Syndrome by the Combination Use of Diane-35 and Metformin

    FavorávelEstudo LaboratorialSíndrome dos Ovários PolicísticosAnandamida (AEA)
  215. 2017

    Stimulated CB1 Cannabinoid Receptor Inducing Ischemic Tolerance and Protecting Neuron from Cerebral Ischemia.

    FavorávelMetanáliseAVCAnandamida (AEA)
  216. 2017

    Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges.

  217. 2017

    Targeting fatty acid amide hydrolase as a therapeutic strategy for antitussive therapy.

    FavorávelEstudo em AnimaisTosseAnandamida (AEA)Endocanabinoide (não especificado)+1
  218. 2017

    The cannabinoid system and pain.

  219. 2017

    The Fatty Acid Amide Hydrolase Inhibitor URB937 Ameliorates Radiation-Induced Lung Injury in a Mouse Model

    FavorávelEstudo em AnimaisSíndrome Aguda da RadiaçãoAnandamida (AEA)
  220. 2017

    Δ9-Tetrahydrocannabinol decreases willingness to exert cognitive effort in male rats

  221. 2016

    A Lower Olfactory Capacity Is Related to Higher Circulating Concentrations of Endocannabinoid 2-Arachidonoylglycerol and Higher Body Mass Index in Women

  222. 2016

    Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase

    DesfavorávelEnsaio ClínicoDorInflamaçãoDisfunção Cognitiva
  223. 2016

    Anandamide and its metabolites: what are their roles in the kidney?

  224. 2016

    Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia.

  225. 2016

    Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting.

  226. 2016

    Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes

  227. 2016

    Decreased Expression of Fatty Acid Amide Hydrolase in Women With Polycystic Ovary Syndrome

    FavorávelEstudo LaboratorialSíndrome dos Ovários PolicísticosDisfunção Ovariana
  228. 2016

    Endocannabinoids in the Gut

  229. 2016

    Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease.

  230. 2016

    Enhancement of Anandamide-Mediated Endocannabinoid Signaling Corrects Autism-Related Social Impairment

  231. 2016

    FAAH Gene Variation Moderates Stress Response And Symptom Severity In Patients With Posttraumatic Stress Disorder And Comorbid Alcohol Dependence

    FavorávelEnsaio ClínicoDependência QuímicaDependência — ÁlcoolTEPT
  232. 2016

    Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.

    FavorávelEstudo em AnimaisDoença de ParkinsonOutros Compostos Relacionados
  233. 2016

    Interactions between dietary oil treatments and genetic variants modulate fatty acid ethanolamides in plasma and body weight composition

    FavorávelEnsaio Clínico Duplo-CegoObesidadeSíndrome MetabólicaAnandamida (AEA)Endocanabinoide (não especificado)+2
  234. 2016

    Involvement Of Endocannabinoids In Alcohol "Binge" Drinking: Studies Of Mice With Human Fatty Acid Amide Hydrolase Genetic Variation And After CB1 Receptor Antagonists

  235. 2016

    Modulation of cellular redox homeostasis by the endocannabinoid system.

  236. 2016

    Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers

    FavorávelEnsaio ClínicoDorDependência QuímicaCâncerAnandamida (AEA)THC:CBD Farmacêutico+13
  237. 2016

    Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid

    FavorávelEstudo em AnimaisTranstornos de ComportamentoAutismo
  238. 2016

    Spatial Distribution of the Cannabinoid Type 1 and Capsaicin Receptors May Contribute to the Complexity of Their Crosstalk

    FavorávelEstudo LaboratorialAnandamida (AEA)Capsaicina (CAPS)
  239. 2016

    Systemic and spinal administration of FAAH, MAGL inhibitors and dual FAAH/MAGL inhibitors produce antipruritic effect in mice.

    FavorávelEstudo em AnimaisPruridoMonoacilglicerol Lipase (MAGL)
  240. 2016

    The endocannabinoid system and bone.

    FavorávelMetanáliseOsteoporoseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
  241. 2016

    The Endocannabinoid System in the Retina: From Physiology to Practical and Therapeutic Applications.

  242. 2016

    The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease.

  243. 2016

    Therapeutic Use of Cannabis in Inflammatory Bowel Disease.

  244. 2015

    A runner’s high depends on cannabinoid receptors in mice

    FavorávelEstudo em AnimaisDorAnsiedadeDor — AgudaAnandamida (AEA)Exercício Físico
  245. 2015

    An Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical Trials

  246. 2015

    Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?

  247. 2015

    Elevated Levels of Endocannabinoids in Chronic Hepatitis C May Modulate Cellular Immune Response and Hepatic Stellate Cell Activation

    InconclusivoEstudo LaboratorialHepatiteAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  248. 2015

    Endocannabinoid-mediated Improvement on a Test of Aversive Memory in a Mouse Model of Fragile X Syndrome

    FavorávelEstudo em AnimaisSíndrome do X FrágilAnandamida (AEA)Canabinoides Sintéticos AM-x
  249. 2015

    Evidence for a Role of Adolescent Endocannabinoid Signaling in Regulating HPA Axis Stress Responsivity and Emotional Behavior Development.

  250. 2015

    FAAH genetic variation enhances fronto-amygdala function in mouse and human

    FavorávelEnsaio ClínicoAnsiedadeTEPT
  251. 2015

    Fetal endocannabinoids orchestrate the organization of pancreatic islet microarchitecture.

    FavorávelEstudo em AnimaisDiabetesAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  252. 2015

    Inhibition of anandamide hydrolysis enhances noradrenergic and GABAergic transmission in the prefrontal cortex and basolateral amygdala of rats subjected to acute swim stress

  253. 2015

    Novel associations between FAAH genetic variants and postoperative central opioid-related adverse effects

    DesfavorávelEnsaio ClínicoNáusea e VômitoAnandamida (AEA)Endocanabinoide (não especificado)
  254. 2015

    Palmitoyl Serine: An Endogenous Neuroprotective Endocannabinoid-Like Entity After Traumatic Brain Injury

  255. 2015

    Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome

    FavorávelMetanáliseDorInflamaçãoDor — CrônicaPalmitoiletanolamida (PEA)+2
  256. 2015

    Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection

  257. 2015

    The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases.

  258. 2015

    The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C]CURB

    FavorávelEstudo LaboratorialDependência QuímicaAnsiedadeEndocanabinoide (não especificado)
  259. 2014

    A New Generation Fatty Acid Amide Hydrolase Inhibitor Protects Against Kainate-induced Excitotoxicity.

  260. 2014

    Association of the c.385C>A (p.Pro129Thr) polymorphism of the fatty acid amide hydrolase gene with anorexia nervosa in the Japanese population

    InconclusivoMetanáliseAnorexia (perda de apetite)Anorexia Nervosa
  261. 2014

    Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

  262. 2014

    Cannabinoids and the Endocannabinoid System in Lower Urinary Tract Function and Dysfunction

    FavorávelMetanáliseInfecção UrináriaAnandamida (AEA)
  263. 2014

    Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system

  264. 2014

    Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity.

  265. 2014

    Decreased enteric fatty acid amide hydrolase activity is associated with colonic inertia in slow transit constipation

    FavorávelEnsaio ClínicoConstipação
  266. 2014

    Experimental Cannabinoid 2 Receptor-Mediated Immune Modulation in Sepsis.

    FavorávelEstudo em AnimaisSepseCanabinoides Sintéticos AM-xMonoacilglicerol Lipase (MAGL)+1
  267. 2014

    Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH)

  268. 2014

    Harnessing the anti-inflammatory potential of palmitoylethanolamide

  269. 2014

    In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects

  270. 2014

    Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects

  271. 2014

    Long-term consequences of perinatal fatty acid amino hydrolase inhibition

  272. 2014

    Moderate-vigorous physical activity across body mass index in females: moderating effect of endocannabinoids and temperament

  273. 2014

    Palmitoylethanolamide in CNS health and disease

  274. 2014

    Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features

    InconclusivoEstudo LaboratorialCâncerCâncer — Linfoma
  275. 2014

    Role of the basolateral amygdala in mediating the effects of the fatty acid amide hydrolase inhibitor URB597 on HPA axis response to stress.

    FavorávelEstudo em AnimaisCanabinoides Sintéticos AM-x
  276. 2013

    Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment

  277. 2013

    Bioactive lipid mediators in skin inflammation and immunity

  278. 2013

    CB1 Cannabinoid Receptors Couple to Focal Adhesion Kinase to Control Insulin Release.

    FavorávelEstudo em AnimaisDiabetesAnandamida (AEA)Endocanabinoide (não especificado)+6
  279. 2013

    Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study

  280. 2013

    Elevated anandamide and related N-acylethanolamine levels occur in the peripheral blood of women with ectopic pregnancy and are mirrored by changes in peripheral fatty acid amide hydrolase activity

    InconclusivoMetanáliseGestaçãoAnandamida (AEA)Outros Compostos Relacionados+1
  281. 2013

    Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study

  282. 2013

    Endocannabinoids in the Brainstem Modulate Dural Trigeminovascular Nociceptive Traffic via CB1 and “Triptan” Receptors: Implications in Migraine

    FavorávelEstudo em AnimaisEnxaquecaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+3
  283. 2013

    Inhibition of endocannabinoid degradation in experimental endotoxemia reduces leukocyte adhesion and improves capillary perfusion in the gut.

  284. 2013

    Targeting the Endocannabinoid System to Treat Sepsis.

    FavorávelMetanáliseSepseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+3
  285. 2012

    Cannabidiol As Potential Anticancer Drug

  286. 2012

    Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

    FavorávelEnsaio Clínico Duplo-CegoPsicoseEsquizofreniaAnandamida (AEA)Outros Compostos Relacionados
  287. 2012

    Endocannabinoid Signaling, Glucocorticoid-Mediated Negative Feedback and Regulation of the HPA Axis.

    FavorávelMetanáliseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  288. 2012

    Enhanced vasorelaxant effects of the endocannabinoid-like mediator, oleamide, in hypertension.

  289. 2012

    Fear-induced suppression of nociceptive behaviour and activation of Akt signalling in the rat periaqueductal grey: role of fatty acid amide hydrolase

    InconclusivoEstudo em AnimaisDorDor — Aguda
  290. 2012

    Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseases

  291. 2012

    Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1

    FavorávelEstudo em AnimaisFibroseEsclerose SistêmicaFibrose — Cutânea
  292. 2012

    Mast cell–glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide

  293. 2012

    Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system

  294. 2012

    Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions

    FavorávelEstudo em AnimaisInflamaçãoArtriteArtrite — Osteoartrite+1
  295. 2012

    Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea

    InconclusivoEnsaio Clínico Duplo-CegoSíndrome do Intestino IrritávelDiarreiaTetraidrocanabinol (THC)
  296. 2012

    The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity

  297. 2011

    Adipose tissue endocannabinoid system gene expression: depot differences and effects of diet and exercise

  298. 2011

    Behavioral effects of fatty acid amide hydrolase inhibition on morphine withdrawal symptoms

    FavorávelEstudo em AnimaisDependência QuímicaDependência — OpioidesAnandamida (AEA)
  299. 2011

    Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress.

    FavorávelMetanáliseDorDoenças Cardiovasculares (DCV)Depressão+11
  300. 2011

    Corticosterone Mediates Reciprocal Changes in CB1 and TRPV1 Receptors in Primary Sensory Neurons in the Chronically Stressed Rat

    InconclusivoEstudo em AnimaisCanabinoides Sintéticos WIN-x
  301. 2010

    Functional Interactions between Stress and the Endocannabinoid System: From Synaptic Signaling to Behavioral Output

    FavorávelMetanáliseAnandamida (AEA)Endocanabinoide (não especificado)+1
  302. 2003

    Modulation of anxiety through blockade of anandamide hydrolysis

    FavorávelEstudo em AnimaisAnsiedade
  303. 1997

    Molecular characterization of human and mouse fatty acid amide hydrolases

    InconclusivoEstudo Laboratorial

Continue por aqui

Perguntas frequentes

Quantos estudos sobre hidrolase de amidas de ácidos graxos (faah) estão indexados no acervo?
São 358 estudos, publicados entre 1997 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 173 · Estudo em Animais: 102 · Ensaio Clínico: 31 · Estudo Laboratorial: 28 · Ensaio Clínico Duplo-Cego: 20 · Metanálise Clínica: 4. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 288 favoráveis, 57 inconclusivos e 13 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Hidrolase de Amidas de Ácidos Graxos (FAAH) — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/canabinoide/hidrolase-de-amidas-de-acidos-graxos-faah/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Hidrolase de Amidas de Ácidos Graxos (FAAH) — estudos científicos sobre cannabis. https://cannabisindica.com.br/canabinoide/hidrolase-de-amidas-de-acidos-graxos-faah/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.